Abiraterone Acetate (New Therapeutic Indication) -- Benefit Assessment According to §35a Social Code Book V [Internet].

The aim of this report is to assess the added benefit of abiraterone compared with watchful waiting while maintaining conventional androgen deprivation therapy (ADT) according to approval for the following therapeutic indication: treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of ADT in whom chemotherapy is not yet clinically indicated.

http://ift.tt/2ruBgqk